Search This Blog

Prostate Cancer

Proton therapy: A better way to treat prostate cancer - latrobebulletinnews.com

Get link
Facebook
X
Pinterest
Email
Other Apps

- August 26, 2022

[unable to retrieve full-text content]

Proton therapy: A better way to treat prostate cancer  latrobebulletinnews.com

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

- November 05, 2019

Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with BRCA1/2 or ATM alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...

Sentinel lymph node biopsy: What cancer patients should know

- May 07, 2024

cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions

- October 09, 2024

common sign of prostate cancer :: Article Creator Seven Early Warning Signs Of Killer Silent Cancer - All Men Need To Know Prostate cancer is the most common cancer among males in the UK but not everybody knows about the symptoms to look out for - here are seven early warning signs Prostate cancer is the most common cancer among men in the UK ( Image: Getty Images) Thousands of men across the UK are diagnosed with prostate cancer every year. It is the most common cancer among males so it is vitally important for men to know the signs of prostate cancer and how to check for it. According to Cancer Research UK, there are around 55,100 new prostate cancer cases in the UK every year, which is roughly 150 every day. Sadly, there are around 12,000 prostate cancer deaths in the UK every year, an average of 33 a day. Older men are far more susceptible to getting prostate cancer. Between 2017-2098, 34 per cent of diagnosed cases were m...

Powered by Blogger

Theme images by billnoll

Tips to be fit: Should you get prostate cancer screening? - The Philadelphia Tribune

- February 24, 2020

Recent news article have suggested that healthy men don’t need to have routine prostate screenings. At first you might say, “Well I’m healthy. Maybe I’ll skip it this time.” Should you? A few years ago the United States Preventive Services Task Force said in a report that routine “prostate-specific antigen” (PSA) screenings does not save lives. Their conclusion was based on five major clinical studies. The two largest studies conducted in the U.S. and Europe found that the death rates of men who got prostate screenings were virtually the same as those who didn’t. Is this reason enough not to have a routine prostate screenings? What most people and even some doctors don’t understand is that a PSA screening is not a specific test for cancer. It’s a test that can detect abnormalities. It doesn’t identify a particular problem. One doctor put it this way “A PSA screening is like an engine warning light. When it flashes, you can’t tell if a particular spark plug is bad. It tells you on...

Prostate cancer: Noninvasive urine test moves a step closer - Medical News Today

- April 14, 2020

Researchers have identified a unique molecular signature of prostate cancer in urine. This may pave the way for an accurate, noninvasive test for the condition. Share on Pinterest Recent research could help pave the way for a new urine test for prostate cancer. The scientists — from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD — used RNA and other molecules in urine to differentiate between males with prostate cancer and those with nonmalignant prostate conditions or healthy prostates. Prostate cancer is the second most common cancer among males in the United States, after skin cancer. Around 1 in 9 males will receive a diagnosis of this condition in their lifetime. In the U.S. alone, almost 192,000 males will receive a diagnosis in 2020, and over 33,000 will die from the condition. Prostate cancer is highly treatable, especially if a doctor diagnoses it early. However, there are often no symptoms in the early stages, and existing screening tes...

Man With Prostate Cancer Placing His Beliefs on Power of Olive Oil - The Pappas Post

- March 26, 2019

Minimally invasive treatment option for enlarged prostate - PAHomePage.com

- February 28, 2019

Genotype linked to shorter survival in metastatic prostate cancer - Urology Times

- March 02, 2020

Inheriting the adrenal-permissive HSD3B1(1245C) genotype is associated with worse outcomes in low-volume metastatic prostate cancer and might someday help identify patients who could benefit from escalated therapy, according to a recent study. In essence, some patients are genetically predisposed to having their prostate cancers make their own potent androgens, such as testosterone or dihydrotestosterone (DHT), from non-testicular sources, according to study author Nima Sharifi, MD, of Cleveland Clinic Genitourinary Malignancies Research Center, Cleveland. “This comes from germline inheritance of an effectively ‘fast’ enzyme by the gene HSD3B1 that allows for prostate cancer to make these androgens. What this means clinically is that men with low-volume metastatic prostate cancer who inherit this fast form of HSD3B1 treated with medical or surgical castration progress more quickly and have shorter survival compared with men who do not inherit this fast enzyme,” Dr. Sharifi said. Re...

Prostate cancer: Investigating the impact of diet - Medical News Today

- October 23, 2019

A recent review searches for links between dietary choices and prostate cancer. The authors conclude that there may be an association between plant based diets and a decreased risk of prostate cancer, as well as a link between dairy intake and increased risk. Share on Pinterest The relationship between diet and disease will not give up its secrets easily. According to the National Cancer Institute, there will be an estimated 174,650 new cases of prostate cancer in the United States this year. In the U.S., about 11.6% of men will receive a diagnosis of prostate cancer at some point during their lifetime. As with other types of cancer , scientists are still uncovering the full range of risk factors for prostate cancer. Some scientists have turned to nutrition , but — for various reasons — measuring the effect of the diet on disease is notoriously difficult. As one example, food intake can fluctuate wildly from day to day, month to month, and year to year. Also, certain dietary ...

Finasteride Effective in Preventing Prostate Cancer - Targeted Oncology

- February 16, 2019

Ian Thompson, Jr, MD According to the final analysis of the Prostate Cancer Prevention Trial (PCPT), finasteride (Proscar), an agent commonly used to treat lower urinary tract problems and baldness in men, was safe and effective in reducing the risk of prostate cancer. The findings were recently published published in the New England Journal of Medicine . 1 “Finasteride is safe, inexpensive, and effective as a preventive strategy for prostate cancer,” principal investigator Ian Thompson, Jr, MD, chair of SWOG's Genitourinary Cancer committee, and president of CHRISTUS Santa Rosa Hospital Medical Center, said in a press release. “Doctors should share these results with men who get regular prostate-specific antigen (PSA) tests that screen for the presence of prostate cancer. The drug will have its greatest effect in this group of men.” The initial SWOG Cancer Research Network PCPT trial, which was funded by the National Cancer Institute, first opened for enrollmen...

Differences Between a Malignant and Benign Tumor - Verywell Health

- October 30, 2021

If you have been diagnosed with a tumor, the first step your healthcare provider will take is to find out whether it is malignant or benign, as this will affect your treatment plan. In short, the meaning of malignant is cancerous and the meaning of benign is noncancerous. Learn more about how either diagnosis affects your health. Verywell / Joshua Seong What Is a Tumor? A tumor is an abnormal lump or growth of cells. When the cells in the tumor are normal, it is benign. Something just went wrong, and they overgrew and produced a lump. When the cells are abnormal and can grow uncontrollably, they are cancerous cells, and the tumor is malignant. To determine whether a tumor is benign or cancerous, a healthcare provider can take a sample of the cells with a biopsy procedure. Then the biopsy is analyzed under a microscope by a pathologist, a healthcare provider specializing in laboratory science. Benign Tumors: Noncancero...